The estimated Net Worth of Alfred Akirov is at least $6.02 Million dollars as of 14 August 2013. Alfred Akirov owns over 112,330 units of Protalix BioTherapeutics stock worth over $5,111,998 and over the last 12 years Alfred sold PLX stock worth over $903,064.
Alfred has made over 4 trades of the Protalix BioTherapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently Alfred sold 112,330 units of PLX stock worth $567,267 on 14 August 2013.
The largest trade Alfred's ever made was selling 112,330 units of Protalix BioTherapeutics stock on 14 August 2013 worth over $567,267. On average, Alfred trades about 42,666 units every 40 days since 2013. As of 14 August 2013 Alfred still owns at least 4,915,383 units of Protalix BioTherapeutics stock.
You can see the complete history of Alfred Akirov stock trades at the bottom of the page.
Alfred's mailing address filed with the SEC is C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL, L3, 20100.
Over the last 17 years, insiders at Protalix BioTherapeutics have traded over $46,705,936 worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth $4,673,005 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Capital Management Lp Camber, and Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $404,231. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth $90,322.
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase
Protalix BioTherapeutics executives and other stock owners filed with the SEC include: